For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks Consensus Estimate for quarterly sales is pegged at $10.13 million ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.72%.